Brokerages expect Assembly Biosciences Inc (NASDAQ:ASMB) to announce $1.68 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Assembly Biosciences’ earnings. The lowest sales estimate is $700,000.00 and the highest is $2.66 million. The business is scheduled to issue its next earnings results on Thursday, March 1st.
On average, analysts expect that Assembly Biosciences will report full year sales of $1.68 million for the current fiscal year, with estimates ranging from $4.40 million to $8.36 million. For the next fiscal year, analysts expect that the company will report sales of $3.82 million per share, with estimates ranging from $2.80 million to $4.83 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Assembly Biosciences.
Several brokerages have recently commented on ASMB. ValuEngine raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 3rd. BidaskClub raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Tuesday, January 30th. Zacks Investment Research cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, January 15th. B. Riley began coverage on shares of Assembly Biosciences in a research report on Friday, January 5th. They set a “neutral” rating and a $35.00 price target on the stock. Finally, Jefferies Group began coverage on shares of Assembly Biosciences in a research report on Wednesday, November 8th. They set a “buy” rating and a $50.00 price target on the stock. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $39.25.
Hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio lifted its holdings in Assembly Biosciences by 66.9% in the third quarter. Strs Ohio now owns 22,700 shares of the biopharmaceutical company’s stock worth $792,000 after acquiring an additional 9,100 shares during the last quarter. California Public Employees Retirement System lifted its holdings in Assembly Biosciences by 118.3% in the second quarter. California Public Employees Retirement System now owns 24,540 shares of the biopharmaceutical company’s stock worth $507,000 after acquiring an additional 13,300 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Assembly Biosciences by 21.2% in the second quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock valued at $12,615,000 after purchasing an additional 107,065 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Assembly Biosciences by 6.9% in the third quarter. JPMorgan Chase & Co. now owns 177,312 shares of the biopharmaceutical company’s stock valued at $5,944,000 after purchasing an additional 11,412 shares during the period. Finally, Schwab Charles Investment Management Inc. acquired a new stake in shares of Assembly Biosciences in the second quarter valued at approximately $484,000. 65.04% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Assembly Biosciences (NASDAQ:ASMB) traded down $1.06 during mid-day trading on Monday, hitting $56.82. 188,403 shares of the stock traded hands, compared to its average volume of 185,067. Assembly Biosciences has a twelve month low of $18.60 and a twelve month high of $58.68. The company has a market capitalization of $1,165.17, a PE ratio of -19.13 and a beta of 0.77.
COPYRIGHT VIOLATION WARNING: This article was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://stocknewstimes.com/2018/02/18/1-68-million-in-sales-expected-for-assembly-biosciences-inc-asmb-this-quarter.html.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.